



HAL
open science

A stretch of residues within the protease-resistant core is not necessary for prion structure and infectivity

Carola Munoz-Montesino, Christina Sizun, Mohammed Moudjou, Laetitia Herzog, Fabienne Reine, Angelique Egalon, Clément Barbereau, Jérôme Chapuis, Danica Ciric, Hubert Laude, et al.

► To cite this version:

Carola Munoz-Montesino, Christina Sizun, Mohammed Moudjou, Laetitia Herzog, Fabienne Reine, et al.. A stretch of residues within the protease-resistant core is not necessary for prion structure and infectivity. *Prion*, 2017, 11 (1), pp.25-30. 10.1080/19336896.2016.1274851 . hal-01603861

HAL Id: hal-01603861

<https://hal.science/hal-01603861v1>

Submitted on 4 Sep 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A stretch of residues within the protease-resistant core is not necessary for prion structure and infectivity.

Carola Munoz-Montesino¹, Christina Sizun², Mohammed Moudjou¹, Laetitia Herzog¹, Fabienne Reine¹, Angelique Igel-Egalon¹, Clément Barbereau¹, Jérôme Chapuis¹, Danica Ciric¹, Hubert Laude¹, Vincent Béringue¹, Human Rezaei¹, and Michel Dron^{1*}

¹VIM, INRA, Université Paris-Saclay, 78350, Jouy-en-Josas, France,

² Institut de Chimie des Substances Naturelles, CNRS, Université Paris Saclay, 91198 Gif-sur-Yvette, France

* Corresponding author

E-mail: michel.dron@inra.fr

Abstract

Mapping out regions of PrP influencing prion conversion remains a challenging issue complicated by the lack of prion structure. The portion of PrP associated with infectivity contains the alpha-helical domain of the correctly folded protein and turns into a beta-sheet-rich insoluble core in prions. Deletions performed so far inside this segment essentially prevented the conversion. Recently we found that deletion of the last C-terminal residues of the helix H2 was fully compatible with prion conversion in the RK13-ovPrP cell culture model, using three different infecting strains. This was in agreement with preservation of the overall PrP^C structure even after removal of up to one-third of this helix. Prions with internal deletion were infectious for cells and mice expressing the wild-type PrP and they retained prion strain-specific characteristics. We thus identified a piece of the prion domain that is neither necessary for the conformational transition of PrP^C nor for the formation of a stable prion structure.

Mammalian prions consist of beta-sheet-rich assemblies of the PrP protein (1, 2). However resolution of their structures remains elusive due to the insolubility and heterogeneity of these aggregates. While the correctly folded protein (PrP^C) contains three helices (3), biophysical data indicate that there is no more alpha helical content in prions (PrP^{Sc}) (4). Different structural models of PrP^{Sc} were proposed, most of them postulating an alternation of beta strand and loops or turns (5-7). It is thus conceivable that some stretches of the protein especially those included in the unstructured regions are not absolutely indispensable for mammalian prion. To support this hypothesis, we may recall that deletions inside the loop joining the two rungs of beta-sheets of the solenoid were compatible with production of functional HET-s prions in *Podospora Anserina* (8). Whether completeness of the “90-231” segment of PrP associated with the infectivity (2, 9) is required for mammalian prions was not clearly answered. Indeed although many inside deletions were done, so far they failed to generate prion entities still able to convert the wild-type PrP^C (10-12). We knew from our previous work that the sequence specificity of the C-terminal part of PrP helix H2 was not essential for prions, even if this sequence is highly conserved in mammalian PrP. Indeed, insertion of eight extra amino acids in the last turns of the helix did not impair prion conversion (13). This observation suggested that the C-terminal residues of H2 were not involved in the backbone of the prion structure but might rather be, or be included into an unstructured or poorly structured part of PrP^{Sc}. Other studies indicating that sequence changes in this area appear to be compatible with prion conversion support this hypothesis (14-16). It was thus appealing to delete the region to determine the impact on PrP^C structure and prion replication. We performed a series of deletions (Fig. 1) and found that removal of the last five residues of the helix H2 did not impair prion conversion (17). This was the first clear-cut demonstration that a stretch of residues within the prion-associated domain of PrP is dispensable to generate *bona fide* prions.

The overall structure of PrP^C is maintained even after removal of one-third of helix H2. Structural integrity of the PrP deletion mutants was first assessed by perturbation analysis based on amide chemical shifts, which are sensitive to conformational changes. Perturbations, though wider spread with the $\Delta 190-197$ than the $\Delta 193-196$ deletion, remain localized in the H2-H3 hairpin (Fig. 2A). This was confirmed by comparison of 3D NMR structures of wild-type and mutant PrPs (Fig. 2B). The $\Delta 193-196$ deletion shortened H2 by one turn and a half, as expected, but the overall structure of the protein was preserved, which is consistent with the ability of the mutant protein to convert into prion (17). Surprisingly, the $\Delta 190-197$ deletion that removes eight highly conserved amino acids and about one third of H2 did not

substantially alter the structure of the rest of the protein. The strong lock provided by the 182C-217C disulfide bond helped maintaining the relative position of the truncated H2 with respect to H3, despite the tension induced by shortening of the H2-H3 connection. The scaffold formed by aromatic residues was slightly rearranged, but key interactions that drive stacking of H1 onto H3 was conserved. The main conclusion was that the 190-197 segment was not essential for the integrity of PrP structure. Therefore, failure in converting $\Delta 190-197$ PrP^C in cells or in cell-free conversion assay by protein misfolding cyclic amplification (PMCA) was not associated with a direct effect of the deletion on the structure of the protein. This would be rather associated with the extended size of the deletion that prevents the conversion process of PrP^C or the establishment of a stable misfolded PrP^{Sc} structure.

The C-terminus of PrP helix 2 is not required for prion conversion. Ectopic expression of PrP from different mammals is known to confer prion susceptibility to RK13 cells (18). Populations of stably transfected RK13 cells were selected to express a series of ovine PrP with increasing H2 C-terminal deletions. Mutant PrP^C were mainly glycosylated and correctly routed to the cell surface. Cells were exposed to prions and analysed for proteinase K resistant PrP^{Sc} content (PrP^{res}) on subsequent passages of the cultures. Ovine PrP^C deleted of amino acids TTTT ($\Delta 193-196$) or TTTTK ($\Delta 193-197$) were successfully converted into PrP^{Sc} upon infection by each of the prion strains assayed: 127S, LA21K fast, T1^{Ov} and T2^{Ov}. The 127S and LA21K fast prions are derived from sheep scrapie isolates and rapidly induce a prion disease in tg338 mice overexpressing ovine PrP (19). T1^{Ov} and T2^{Ov} are two prion strains isolated on adaptation of a human sporadic CJD case to tg338 mice (20). We found that PrP $\Delta 193-196$ and PrP $\Delta 193-197$ conferred to RK13 cells the same degree of susceptibility to 127S infection than the wild-type protein (17). The levels of PrP^{res} accumulated in cells also compared at least up to 12 passages of the cultures. The size distribution of cell-formed PrP^{res} aggregates was assessed by sedimentation velocity and found to be the same for the wild-type and mutant proteins (Fig. 3). However we noted the presence of an additional, more N-terminally truncated PrP^{res} fragment in cells expressing the deleted PrPs. This might reflect a stronger cell processing of Δ PrP^{Sc} or the production of some variant structures. However, PrP^{res} species with the expected size were always predominant. Populations of cells infected by either T1^{Ov} or T2^{Ov} also produced high amounts of mutant PrP^{res} from the first passage onwards and at least for eight passages post infection. This was rather unexpected, as populations of RK13 cells expressing the wild-type PrP^C were not found susceptible to T1^{Ov} or T2^{Ov}. Only one subclone selected for its substantially increased susceptibility to prions was found to be really permissive to these agents (20). Removal of one additional residue (V192)

dramatically reduced replication of 127S prion in RK13 cells but had only a weaker impact on T1^{Ov} and T2^{Ov}. Extending further the deletion to generate Δ 190-197 conferred resistance to the three prion strains. Unpublished results indicate that this is the larger size of the deletion rather than the specific absence of the amino acids 190 and 191 that prevented the conversion. Altogether we have shown that the 193-196/7 H2 C-terminal part is not necessary for the efficient conversion of PrP^C into a self-perpetuating protease-resistant form. However we noticed that removal of these residues can introduce some effects on PrP^{res} presentation and can even favour the replication of certain prion strains difficult to propagate in this cellular context, such as T1^{Ov} and T2^{Ov}. Also PrPins193 (13), a mutant with an insertion of eight extra amino acids modifying the H2 end was found convertible into PrP^{Sc} following T1^{Ov} infection, while wild-type PrP^C was not. Whether modification or removal of the last turns of helix H2 facilitates somehow the unfolding of PrP^C and thus its conversion by certain prion strains, remains to be determined.

Prions with an internal deletion are infectious and transfer the strain-specific information. We further showed that PrP^{Sc} lacking residues 193-196 or 193-197 were infectious for naïve homologous and wild-type PrP expressing cells. Δ PrP^{Sc} were also efficient seeds for PMCA. They produced a stereotyped prion disease upon inoculation to tg338 mice, which expressed the wild-type ovine PrP. It is commonly thought that prion strain-specific characteristics are encoded within differences in PrP^{Sc} structures or assemblies. Δ PrP^{Sc} induced a phenotype in tg338 mice that was superimposable to the parental prions used for cell culture infections. In particular, PrP^{res} electrophoretic signature and neuroanatomical deposition in the infected mouse brain were conserved. Altogether these observations indicate that the strain-specific information was not lost through the propagation of prions on mutant PrPs. This suggested that the structural determinants of prion strains were maintained despite removal of the internal residues.

Conclusion and perspectives. We have shown that a short portion inside the “90-231” segment of PrP is not essential to establish a stable, self-propagating prion structure and to allow PrP^C to undertake the conformational change. Moreover removal of residues corresponding to the H2 C-terminus in PrP^C does not impair the encoding of prion strain-specific information. Are there or not other parts of the infectivity-associated domain of PrP that are dispensable for prion structure? The answer to this question is important but represents a real challenge as the introduction of significant sequence changes, particularly in the globular domain, can alter PrP^C structure or routing to the cell surface and thereby may prevent conversion even though the area might not be crucial for the structure of prions. New

approaches such as the “cell-based mb-PMCA” (21) might overcome some of these limitations.

Legends

Figure 1. Map of deletions on ovine PrP.

Amino acid sequence of the C-terminal part of PrP. Residues of the alpha helices are in black and those located in unstructured areas are in blue. The two cysteines of the disulfide bridge linking H2 to H3 are in purple and asparagines of the two glycosylation sites in bold. Deletions are indicated by red lines.

Figure 2. Structural analysis of deletion mutants.

(A) Perturbation analysis was performed by measuring amide ^1H , ^{15}N chemical shift deviations ($\Delta\delta$) for PrP Δ 193-196 (blue) and PrP Δ 190-197 (red). The results are mapped on the PrP structure (in cartoon). Colored spheres represent amide nitrogen atoms with $\Delta\delta > 0.1$ ppm in blue and red for each mutant, in magenta if deviations are observed in both. Yellow and green spheres indicate deleted residues in the mutants.

(B) NMR structure ensembles of wild-type PrP and deletion mutants are shown in cartoon, without the disordered N-terminus. The disulfide bond (yellow), Phe (blue) and Tyr (cyan) side chains are represented in sticks. Deletions are indicated with a red cylinder.

Figure 3. Size distribution of wild-type and mutant PrP^{res} aggregates accumulated in infected cells.

Lysates of 127S-infected cells were solubilized in detergents, centrifuged on a continuous 10–25% iodixanol gradient (Optiprep, Axys-shield) and fractionated to separate PrP^{res} assemblies by sedimentation velocity (19). Thirty fractions were recovered, PK-treated and analysed of PrP^{res} content by immunoblotting. The graph shows quantification of PrP^{res} signals from the top to the bottom of the gradient for wild-type (black lane) and Δ 193-196 mutant (red line).

Reference

1. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. *Biochemistry*. 1991;30(31):7672-80. PubMed PMID: 1678278.
2. Prusiner SB. Prions. *Proc Natl Acad Sci U S A*. 1998;95(23):13363-83. PubMed PMID: 9811807.
3. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. NMR structure of the mouse prion protein domain PrP(121-231). *Nature*. 1996;382(6587):180-2. PubMed PMID: 8700211.
4. Baron GS, Hughson AG, Raymond GJ, Offerdahl DK, Barton KA, Raymond LD, et al. Effect of glycans and the glycoposphatidylinositol anchor on strain dependent conformations of scrapie prion protein: improved purifications and infrared spectra. *Biochemistry*. 2011;50(21):4479-90. PubMed PMID: 21539311.
5. Requena JR, Wille H. The structure of the infectious prion protein: experimental data and molecular models. *Prion*. 2014;8(1):60-6. Epub 2014/03/04. PubMed PMID: 24583975.
6. Groveman BR, Dolan MA, Taubner LM, Kraus A, Wickner RB, Caughey B. Parallel in-register intermolecular beta-sheet architectures for prion-seeded prion protein (PrP) amyloids. *J Biol Chem*. 2014;289(35):24129-42. Epub 2014/07/17. doi: 10.1074/jbc.M114.578344. PubMed PMID: 25028516; PubMed Central PMCID: PMC4148845.
7. Silva CJ, Vazquez-Fernandez E, Onisko B, Requena JR. Proteinase K and the structure of PrP^{Sc}: The good, the bad and the ugly. *Virus Res*. 2015;207:120-6. doi: 10.1016/j.virusres.2015.03.008. PubMed PMID: 25816779.
8. Ritter C, Maddelein ML, Siemer AB, Luhrs T, Ernst M, Meier BH, et al. Correlation of structural elements and infectivity of the HET-s prion. *Nature*. 2005;435(7043):844-8. Epub 2005/06/10. doi: 10.1038/nature03793. PubMed PMID: 15944710; PubMed Central PMCID: PMC1567094.
9. Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. *Embo J*. 1996;15(6):1255-64. PubMed PMID: 8635458.
10. Supattapone S, Bosque P, Muramoto T, Wille H, Aagaard C, Peretz D, et al. Prion protein of 106 residues creates an artificial transmission barrier for prion replication in transgenic mice. *Cell*. 1999;96(6):869-78. Epub 1999/04/02. PubMed PMID: 10102274.
11. Vorberg I, Chan K, Priola SA. Deletion of beta-strand and alpha-helix secondary structure in normal prion protein inhibits formation of its protease-resistant isoform. *J Virol*. 2001;75(21):10024-32. Epub 2001/10/03. doi: 10.1128/JVI.75.21.10024-10032.2001. PubMed PMID: 11581371; PubMed Central PMCID: PMC114577.
12. Taguchi Y, Mistica AM, Kitamoto T, Schatzl HM. Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein. *PLoS Pathog*. 2013;9(6):e1003466. Epub 2013/07/05. doi: 10.1371/journal.ppat.1003466. PubMed PMID: 23825952; PubMed Central PMCID: PMC3694865.
13. Salamat K, Moudjou M, Chapuis J, Herzog L, Jaumain E, Beringue V, et al. Integrity of helix 2-helix 3 domain of the PrP protein is not mandatory for prion replication. *J Biol Chem*. 2012;287(23):18953-64. PubMed PMID: 22511770.



14. Geissen M, Mella H, Saalmuller A, Eiden M, Proft J, Pfaff E, et al. Inhibition of prion amplification by expression of dominant inhibitory mutants--a systematic insertion mutagenesis study. *Infect Disord Drug Targets*. 2009;9(1):40-7. Epub 2009/02/10. PubMed PMID: 19200014.
15. Hafner-Bratkovic I, Bester R, Pristovsek P, Gaedtke L, Veranic P, Gaspersic J, et al. Globular domain of the prion protein needs to be unlocked by domain swapping to support prion protein conversion. *J Biol Chem*. 2011;286(14):12149-56. Epub 2011/02/18. doi: 10.1074/jbc.M110.213926. PubMed PMID: 21324909; PubMed Central PMCID: PMC3069419.
16. Shirai T, Saito M, Kobayashi A, Asano M, Hizume M, Ikeda S, et al. Evaluating prion models based on comprehensive mutation data of mouse PrP. *Structure*. 2014;22(4):560-71. Epub 2014/02/25. doi: 10.1016/j.str.2013.12.019. PubMed PMID: 24560805.
17. Munoz-Montesino C, Sizun C, Moudjou M, Herzog L, Reine F, Chapuis J, et al. Generating Bona Fide Mammalian Prions with Internal Deletions. *J Virol*. 2016;90(15):6963-75. doi: 10.1128/JVI.00555-16. PubMed PMID: 27226369; PubMed Central PMCID: PMC4944278.
18. Vilette D. Cell models of prion infection. *Vet Res*. 2008;39(4):10. doi: 10.1051/vetres:2007049. PubMed PMID: 18073097.
19. Tixador P, Herzog L, Reine F, Jaumain E, Chapuis J, Le Dur A, et al. The physical relationship between infectivity and prion protein aggregates is strain-dependent. *PLoS Pathog*. 2010;6(4):e1000859. Epub 2010/04/27. doi: 10.1371/journal.ppat.1000859. PubMed PMID: 20419156; PubMed Central PMCID: PMC2855332.
20. Chapuis J, Moudjou M, Reine F, Herzog L, Jaumain E, Chapuis C, et al. Emergence of two prion subtypes in ovine PrP transgenic mice infected with human MM2-cortical Creutzfeldt-Jakob disease prions. *Acta Neuropathol Commun*. 2016;4(1):10. doi: 10.1186/s40478-016-0284-9. PubMed PMID: 26847207; PubMed Central PMCID: PMC4743415.
21. Moudjou M, Chapuis J, Mekrouti M, Reine F, Herzog L, Sibille P, et al. Glycoform-independent prion conversion by highly efficient, cell-based, protein misfolding cyclic amplification. *Sci Rep*. 2016;6:29116. doi: 10.1038/srep29116. PubMed PMID: 27384922; PubMed Central PMCID: PMC4935985.

Helix 2

Δ193-196/197

Helix 3

---Y**S**NQNNFVHD**C**VNITVKQHTVTTTT**K**GEN**F**TETDIKIMERVVEQM**C**ITQYQRESQAY**Y**Q**R**G**A**S – GPI anchor
Δ190-197

A**B**